Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AAA

Ratings ESG MSCI

Ratings Gilead Sciences, Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Gilead Sciences, Inc.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Gilead Sciences, Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With an enterprise value anticipated at 6.12 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.

Rating Financials

Gilead Sciences, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Gilead Sciences, Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Gilead Sciences, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Gilead Sciences, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Gilead Sciences, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
180B
AAA
873B
A
583B
BBB
398B
AA
324B
AA
297B
A
294B
AAA
287B
A
198B
A
169B
A
Average 360.45B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Ratings Gilead Sciences, Inc.
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW